The basal ganglia are involved in the integration of sensorimotor, associative, and limbic information to produce motor behaviors. The central component of these structures, the striatum, integrates excitatory glutamatergic inputs from cortex, thalamus, and limbic areas, with dopaminergic inputs from mesencephalon. It is composed of a large proportion of medium-sized spiny output neurons (95%) and of interneurons (5%). Striatal output neurons are GABAergic and project to either substantia nigra (pars reticulata) or globus pallidus and differ in their neuropeptide content: the striatonigral pathway contains substance P/dynorphin and the striatopallidal enkephalin (for review, see Graybiel, 1990; Gerfen and Wilson, 1996) . Dopamine regulates striatal neurotransmission via two types of receptor families, D 1 -type (D 1 and D 5 ) and D 2 -type (D 2 , D 3 , D 4 ) receptors, which have distinct pharmacological profiles and mechanisms of transduction (Creese et al., 1983; Jaber et al., 1996) . It has been suggested that dopamine differentially regulates the two striatal output pathways and that a balanced control is essential for the proper function of the extrapyramidal motor system (for review, see Alexander and Crutcher, 1990; Gerfen, 1992) . Accordingly, several anatomical studies have demonstrated a segregation of D 1 and D 2 receptors, respectively, in striatonigral/ substance P and striatopallidal/enkephalin neurons Le Moine et al., 1990a Hersch et al., 1995; Bloch, 1995, 1996; Yung et al., 1996) . However, many physiological data indicate synergistic effects after coactivation of D 1 -and D 2 -type receptors (for review, see Waddington and Daly, 1993; White and Hu, 1993) .
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The basal ganglia are involved in the integration of sensorimotor, associative, and limbic information to produce motor behaviors. The central component of these structures, the striatum, integrates excitatory glutamatergic inputs from cortex, thalamus, and limbic areas, with dopaminergic inputs from mesencephalon. It is composed of a large proportion of medium-sized spiny output neurons (95%) and of interneurons (5%). Striatal output neurons are GABAergic and project to either substantia nigra (pars reticulata) or globus pallidus and differ in their neuropeptide content: the striatonigral pathway contains substance P/dynorphin and the striatopallidal enkephalin (for review, see Graybiel, 1990; Gerfen and Wilson, 1996) . Dopamine regulates striatal neurotransmission via two types of receptor families, D 1 -type (D 1 and D 5 ) and D 2 -type (D 2 , D 3 , D 4 ) receptors, which have distinct pharmacological profiles and mechanisms of transduction (Creese et al., 1983; Jaber et al., 1996) . It has been suggested that dopamine differentially regulates the two striatal output pathways and that a balanced control is essential for the proper function of the extrapyramidal motor system (for review, see Alexander and Crutcher, 1990; Gerfen, 1992) . Accordingly, several anatomical studies have demonstrated a segregation of D 1 and D 2 receptors, respectively, in striatonigral/ substance P and striatopallidal/enkephalin neurons Le Moine et al., 1990a Hersch et al., 1995; Bloch, 1995, 1996; Yung et al., 1996) . However, many physiological data indicate synergistic effects after coactivation of D 1 -and D 2 -type receptors (for review, see Waddington and Daly, 1993; White and Hu, 1993) .
In the basal ganglia A 2A receptors are restricted to striatopallidal/D 2 -containing neurons and, in contrast to D 2 receptors, are not present on dopaminergic nerve terminals and are virtually absent from cholinergic interneurons (Schiffmann et al., 1991; Fink et al., 1992; Augood and Emson, 1994; Svenningsson et al., 1997 ). An alternative way to investigate how D 1 /D 2 interactions occur is to study how adenosine modulates neurotransmission via adenosine A 2A receptors and how they can be involved in interactions with D 1 receptor-mediated effects. Indeed, it has been shown that dopamine acting on D 2 receptors and adenosine acting on A 2A receptors have opposing actions on neurotransmitter release, gene expression, and several motor behaviors (for review, see Ferré et al., 1992; Ongini and Fredholm, 1996) . Accordingly, selective A 2A antagonists share with D 2 agonists the ability to potentiate motor effects induced by D 1 receptor agonists as well as D 1 -induced c-fos expression in dopamine-depleted striatum (Jiang et al., 1993; Pinna et al., 1996; Pollack and Fink, 1996) .
In this context, detailed analysis of the modulation of D 1 or D 2 agonist-mediated effects by an A 2A antagonist may help to elucidate the D 1 / D 2 interactions in the basal ganglia. We therefore used sensitive in situ hybridization with riboprobes to examine how pharmacological treatments involving dopamine or adenosine receptors might up-or downregulate the expression of c-fos in the basal ganglia. In particular, c-fos expression was studied in phenotypically identified striatal neurons, with double-labeling, after challenges with selective compounds acting at D 1 , D 2 , and A 2A receptors given alone or in combination.
MATERIALS AND METHODS
Pharmacolog ical manipulations and tissue preparation. All experiments have been performed in accordance with the guidelines of the French Agriculture and Forestry Ministry (decree 87849, license 01499) and with the C entre National de la Recherche Scientifique approval. Adult male Sprague Dawley rats (200 -280 gm) (Iffa Credo, France) were maintained in standard housing conditions several days before the experiments. Animals were treated with systemic injections of saline (NaC l 0.9%); ϮSK F-82958 (Research Biochemicals, Natick, M A), a f ull dopamine receptor agonist that has a 200-fold selectivity for D 1 over D 2 receptors (Andersen and Jansen, 1990) ; quinelorane or LY-163,502 (Research Biochemicals), a dopamine receptor agonist that conversely shows at least a 50-fold selectivity for D 2 over D 1 receptors (Bymaster et al., 1986; Andersen and Jansen, 1990); or SCH-58261 (Schering-Plough, Milan, Italy) , an adenosine receptor antagonist that is 60-fold selective for A 2A over A 1 receptors (Z occhi et al., 1996) . All rats had been handled the day before the injection and had received two injections. The different treatment groups were as follows: saline plus saline (n ϭ 5), quinelorane 2 mg / kg plus saline (n ϭ 4), SK F-82958 0.5 mg / kg plus saline (n ϭ 3), SK F-82958 1 mg / kg plus saline (n ϭ 5), SK F-82958 2 mg / kg plus saline (n ϭ 2), SCH-58261 5 mg / kg plus saline (n ϭ 4), SK F-82958 1 mg / kg plus quinelorane 2 mg / kg (n ϭ 5), SK F-82958 1 mg / kg plus SCH-58261 5 mg/kg (n ϭ 4), or quinelorane 2 mg / kg plus SCH-58261 5 mg / kg (n ϭ 5). SK F-82958 and quinelorane were dissolved in saline, whereas SCH-58261 was dissolved in saline/5% T ween 80 after caref ul sonication. Drugs were injected intraperitoneally, 0.5 ml per injection, and the rats were decapitated 1 hr after the injections. The brains were dissected out, frozen over liquid nitrogen, and then sectioned into 10 m sections, collected on gelatin-coated slides, and stored at Ϫ80°C until used.
Probe synthesis. 35 S-labeled cRNA probes were prepared by in vitro transcription from cDNA clones corresponding to fragments of the rat c-fos cDNA (Curran et al., 1987 ) (a gift from Dr. T. Curran, Roche Institute of Molecular Biology, Nutley, NJ), rat D 1 and D 2 dopamine receptor cDNAs (Monsma et al., 1989 ) (a gift from Dr. D. Sibley, National Institute of Health, N I N DS, Bethesda, MD), and rat -opioid receptor cDNA (Thompson et al., 1993 ) (a gift from Dr. S. J. Watson, University of Michigan, Ann Arbor, M I). Transcriptions were performed from 50 ng of linearized plasmid, using either 35 S-UTP (Ͼ1000 C i /mmol; DuPont de Nemours, Les Ulis, France) or digoxigenin-11-UTP (Boehringer Mannheim, Meylan, France) and SP6, T3, or T7 RNA polymerases as described by Le . After alkaline hydrolysis to obtain 250 bp cRNA fragments, the 35 S-labeled probes were purified on G50-Sephadex. The 35 S-labeled probes and the digoxigenin-labeled probes were precipitated in 3 M sodium acetate/absolute ethanol (0.1:2.5, v/ v), pH 5.
Single detection of c-fos mR NA on cr yostat sections. Sections were hybridized as described by Le Bloch (1995, 1996) with minor modifications. Cryostat sections were post-fixed in 4% paraformaldehyde (PFA) for 5 min at room temperature, rinsed twice in 4ϫ SSC, and placed into 0.25% acetic anhydride in 0.1 M triethanolamine/4ϫ SSC, pH 8, for 10 min at room temperature. After dehydration, the sections were hybridized overnight at 55°C with 10 6 cpm of 35 S-labeled cRNA probe in 50 l of hybridization solution (20 mM Tris-HC l, 1 mM EDTA, 300 mM NaC l, 50% formamide, 10% dextran sulfate, 1ϫ Denhardt's, 250 g /ml yeast tRNA, 100 g /ml salmon sperm DNA, 100 mM DTT, 0.1% SDS, and 0.1% sodium thiosulfate). After 20 min of RNase A treatment (20 mg /ml), the sections were washed with 2ϫ SSC (5 min, twice), 1ϫ SSC (5 min), 0.5ϫ SSC (5 min) at room temperature, and rinsed in 0.1ϫ SSC at 65°C (30 min, twice) before dehydration (the latter SSC washes contained 1 mM DTT). Sections either were exposed on x-ray films (Kodak BIOM AX, Rochester, N Y) for 3-6 d or dipped into I lford K5 emulsion, exposed for 7 weeks, developed, and stained with toluidine blue.
Simultaneous detection of c-fos mR NA with D 1 or D 2 mR NAs on cr yostat sections. T wo combinations of probes were used for the simultaneous detection of two mRNAs on a single section: a 35 S-labeled c-fos probe in combination with digoxigenin-labeled D 1 or D 2 probes. Cryostat sections were pretreated as mentioned above. After dehydration the sections were hybridized overnight at 55°C with a combination of 35 S-and digoxigeninlabeled probes (10 6 cpm of 35 S-labeled probe and 10 -20 ng of digoxigenin-labeled probe in 50 l of hybridization solution). After 20 min of RNase A treatment at 37°C (20 g /ml), the slides were washed in various concentrations of SSC as mentioned above, but without DTT. After washing, the sections were put in 0.1ϫ SSC at room temperature and then processed directly for detection of the digoxigenin signal. The sections were rinsed twice for 5 min in buffer A (1 M NaC l, 0.1 M Tris, and 2 mM MgC l 2 , pH 7.5) and then for 30 min in buffer A containing 3% normal goat serum and 0.3% Triton X-100. After 5 hr of incubation at room temperature with alkaline phosphatase-conjugated antidigoxigenin antiserum (Boehringer Mannheim; 1:1000 in buffer A, 3% normal goat serum, and 0.3% Triton X-100), the sections were rinsed in buffer A (5 min, twice) and then for 10 min twice in STM buffer (1 M NaC l, 0.1 M Tris, and 5 mM MgC l 2 , pH 9.5), and finally for 10 min twice in 0.1 M STM buffer, pH 9.5 (0.1 M NaC l, 0.1 M Tris, and 5 mM MgC l 2 , pH 9.5). Then the sections were incubated overnight in the dark at room temperature in 0.1 M STM buffer, pH 9.5, containing 0.34 mg /ml nitroblue tetrazolium and 0.18 mg /ml bromo-chloro-indolylphosphate. They were rinsed in 0.1 M STM buffer, pH 9.5, and then in 1ϫ SSC, dried, and dipped into I lford K5 emulsion (diluted 1:3 in 1ϫ SSC). After being exposed for 10 weeks in the dark, the sections were developed and mounted without counterstaining.
Counting of labeled neurons. Labeled neurons both from single-labeling and double-labeling experiments (exposure times: 7 weeks for single in situ hybridization and 10 weeks for double in situ hybridization) were counted as previously described on similar material (Le . Accordingly, a labeled neuron corresponded to a density of silver grains at least twofold higher than background. One section per animal was analyzed for counting in single in situ hybridization, and one section per animal was counted for the double labeling. The densities of c-fos mRNA-containing neurons were studied in the striatum (ϩ1 mm from bregma) and globus pallidus (Ϫ0.8 mm from bregma) according to Swanson (1992) . The areas examined were 2-4 mm 2 for the caudate putamen and 1.5-2 mm 2 for the globus pallidus. The labeled neurons were counted using an image analyzer system for cartography (HISTO 200, Biocom, Les Ulis, France). For double in situ hybridization, quantification was performed only on the sections with simultaneous detection of c-fos and D 2 mRNAs, and the c-fos mRNA-labeled neurons were divided into two populations: the D 2 mRNA-positive (ϩ) and D 2 mRNA-negative (Ϫ) neurons. The densities of c-fos-expressing neurons (number of c-fos mRNA-positive neurons per mm 2 ) were pooled and averaged for each group, and statistical analysis was performed by a two-way ANOVA, followed by post hoc t tests corrected for the experiment-wise ␣ level by the Bonferroni correction.
RESULTS

Effects of D 1 and D 2 agonists on c-fos expression in the striatum and in the globus pallidus
Under control conditions (i.e., saline-treated rats), neurons containing c-fos mRNA were observed in several cortical areas, especially the endopiriform and piriform cortices, in the septum and in the caudate putamen and nucleus accumbens (Fig. 1) . The densities of c-fos-positive neurons (mean Ϯ SEM) were 35.25 Ϯ 4.34 per mm 2 in the caudate putamen and 24.2 Ϯ 3.4 per mm 2 in the globus pallidus (Table 1) .
One hour after administration of the D 1 agonist SKF-82958 at the dose of 1 mg/kg, the number of c-fos mRNA-containing neurons dramatically increased in the caudate putamen (ϩ277%) and the nucleus accumbens (Figs. 1, 2, Table 1 ). An increase also was found in the cortex (with a particularly high concentration in layer VIb) and in the septum (Fig. 1) . By contrast, the number of c-fos mRNA-containing neurons tended to decrease (by 48%, p ϭ 0.08) in the globus pallidus (Fig. 3, Table 1 ). In all of the examined areas, the effects of SKF-82958 were similar over the dose range tested (0.5-2 mg/kg; data not shown). Conversely, the D 2 agonist quinelorane, at the dose of 2 mg/kg, caused a decrease in the number of c-fos mRNA-containing neurons in the caudate putamen (Ϫ75%, Table 1 ). Detection of such a decrease is directly related to our ability to consistently detect and quantif y c-fos mRNA in basal conditions by using sensitive riboprobes (Fig. 2) . In contrast, the density of labeled neurons in the globus pallidus was increased after treatment with the D 2 agonist (ϩ74%) (Fig. 3, Table 1 ).
When quinelorane (2 mg / kg) was coadministered with SKF-82958 (1 mg / kg), the density of c-fos-labeled neurons in the caudate putamen and the nucleus accumbens was increased to the same extent as after SK F-82958 alone (Table 1) . However, as shown in Figures 1 and 4 , the homogenous distribution of the c-fos mRNA-containing neurons after SK F-82958 treatment was heterogeneous ("patchy") after coadministration of the two drugs. Comparison on adjacent sections shows that the distribution of c-fos mRNA after D 1 plus D 2 agonists was parallel to the distribution of -opioid receptor mRNA (Fig. 4) . At the same time, in the globus pallidus, the coadministration of both SKF-82958 (1 mg/kg) and quinelorane (2 mg/kg) increased by 190% the density of c-fos-labeled neurons as compared with quinelorane alone (Fig. 3, Table 1 ).
Effects of an A 2A antagonist alone or in combination with a D 1 agonist on c-fos expression in the striatum and in the globus pallidus
The adenosine A 2A antagonist SCH-58261 had similar effects to the D 2 agonist quinelorane in the striatum. Treatment with SCH-58261 at a dose of 5 mg/kg induced a decrease in the density of c-fos-labeled neurons in the caudate putamen (Ϫ53%). In contrast to quinelorane, it had no effect on the density of labeled neurons in the globus pallidus (Fig. 5, Table 1 ). The coadministration of SKF-82958 (1 mg/kg) and SCH-58261 (5 mg/kg) induced a further increase in the density of c-fos mRNA-containing neurons in the caudate putamen (ϩ38%) as compared with SKF-82958 alone (Fig. 5, Table 1 ). The distribution pattern of the c-fos-labeled neurons after the coadministration was homoge- Table 1 . Magnification, 40ϫ. neous in the striatum and not patchy, as seen after D 1 plus D 2 agonists (Figs. 1, 2, 4, 5) .
In the globus pallidus the coadministration of SKF-82958 with SCH-58261 induced a dramatic increase in the density of labeled neurons as compared with the saline-treated rats (ϩ188%) but also as compared with SK F-82958 alone (ϩ458%) (Fig. 5, Table 1 ).
Effects of an A 2A antagonist alone or in combination with a D 2 agonist on c-fos expression in the striatum and in the globus pallidus As mentioned above, the D 2 receptor agonist quinelorane (2 mg / kg) decreased the density of c-fos mRNA-containing neurons in the caudate putamen and increased it in the globus pallidus, whereas the A 2A receptor antagonist SCH 58261 (5 mg/kg) affected c-fos mRNA expression only in the caudate putamen, where it caused a decrease in the density of labeled neurons (Table 1 ). The coadministration of D 2 agonist and A 2A antagonist significantly counteracted the decrease induced by quinelorane in the caudate putamen (from Ϫ75 to Ϫ52%). No synergistic effect of the two drugs on c-fos expression was found in the globus pallidus as compared with quinelorane alone (Table 1) .
Phenotypical identification of the c-fos mRNAcontaining neurons in the caudate putamen after D 1 and D 2 agonists, given alone or in combination
To examine in which type of striatal neurons the abovementioned changes in c-fos expression occurred, we used doublelabeling experiments with probes for either D 1 or D 2 receptor mRNA, together with a probe for c-fos mRNA. Because the results, analyzed in two separate experiments (as illustrated in Fig. 6 ), were identical, quantitative data were generated only from c-fos plus D 2 mRNAs simultaneous detection (Table 2 ). Therefore, in the following, D 2 mRNA-negative (Ϫ) neurons are referred to as D 1 mRNA-positive (ϩ) neurons on the basis of both experiments and previously published data (Le Bloch, 1995, 1996) . Figure 6 shows that administration of the D 1 agonist SKF-82958 (1 mg/kg) increased the number of both D 1 and D 2 mRNAcontaining neurons that express c-fos mRNA (Table 2 ). Con- Table 1 . Magnification, 40ϫ. versely, the D 2 agonist quinelorane (2 mg / kg) decreased the density of c-fos-labeled neurons both for D 1 and D 2 mRNAcontaining neurons (Table 2 ). The coadministration of D 1 and D 2 agonists had opposite effects on c-fos expression in these two populations because it induced an increase in the density of c-fos-labeled neurons containing D 1 mRNA and a decrease in the density of c-fos-labeled neurons containing D 2 mRNA, as compared with the D 1 agonist alone (Fig. 6, Table 2 ). Indeed, in SK F-82958 treated rats 53% of the c-fos expressing neurons were D 1 mRNA-positive, whereas in rats treated by SK F-82958 plus quinelorane, the proportion of these neurons reached 91% (Table  2) . Note here and below that the relative changes observed in the density of c-fos-labeled neurons in the caudate putamen are comparable to what was observed in the single-labeling experiments and summarized in Table 1 . Table 2 ). The coadministration of the D 1 agonist and the A 2A antagonist potentiated the increase in the density of c-fos-labeled neurons that were positive for D 1 mRNA but had no effect on the density of c-fos labeled in D 2 mRNA-containing neurons, as compared with the D 1 agonist alone (Table 2) .
Phenotypical identification of the c-fos
Phenotypical identification of the c-fos mRNAcontaining neurons in the caudate putamen after A 2A antagonist and D 2 agonist, given alone or in combination
The density of D 2 mRNA-positive neurons that express c-fos mRNA was lower in SCH-58261 (Ϫ60%) and quineloranetreated animals (Ϫ97%) as compared with saline (Table 2) . At the same time, quinelorane -and not SCH-58261-induced a reduction of c-fos in neurons positive for D 1 mRNA (Ϫ84.5%).
When SCH-58261 and quinelorane were coadministered, there was no synergistic effect on c-fos expression in the D 1 -containing nor in the D 2 -containing neurons (Table 2) . 
Effect of D 2 and D 1 agonists given alone on c-fos expression in the striatum
Selective activation of D 2 receptors by the D 2 agonist produced a significant decrease in the number of striatal neurons expressing c-fos in the caudate putamen. The decrease was found in both D 1 -and D 2 -positive neurons. In D 2 -containing neurons this decrease may be explained by the fact that dopamine is likely to have an inhibitory action on striatopallidal neurons via postsynaptic D 2 receptors . Conversely, the D 2 agonist effect on c-fos in D 1 -containing neurons might be related to activation of presynaptic D 2 autoreceptors located on dopaminergic terminals, because this strongly decreases striatal dopamine release (Imperato et al., 1988; Suaud-Chagny et al., 1991) and thereby the D 1 -mediated activity in striatonigral neurons. Decreases of mRNA coding for the immediate early gene NGFI-A (zif 268) have been described after treatment with drugs acting on D 2 or A 2A receptors (Gerfen et al., 1995; Svenningsson et al., 1995) , but we describe here for the first time the D 2 -mediated inhibition of c-fos expression in the two striatal output neurons.
The full D 1 agonist SKF-82958 increased c-fos expression in the striatum in normal rats, as previously reported by Wang and McGinty (1996) . A strong induction of c-fos expression in the D 1 rich cortical layer VIb (Gaspar et al., 1995) expression in D 1 -positive neurons was expected, because many studies have demonstrated that the dopamine-mediated induction of striatal Fos is dependent on D 1 activation [see Hughes and Dragunow (1995) and references therein]. The increased number of D 2 -positive neurons expressing c-fos after SK F-82958 was unexpected. In previous studies, using the partial D 1 agonist SK F-38393, researchers observed c-fos induction only in the D 1 receptor-containing striatonigral neurons Gerfen et al., 1995) . However, these studies were performed in animals with nigrostriatal lesions, and we therefore suggest that c-fos induction by the D 1 agonist in striatopallidal neurons requires intact nigrostriatal neurons. We hypothesize that the D 1 agonist, when injected systemically, acts on D 1 receptors located on striatonigral terminals (Caillé et al., 1996) and stimulates GABA release (Cameron and Williams, 1993) , which in turn inhibits nigrostriatal neurons and decreases the extracellular striatal dopamine level (Suaud-Chagny et al., 1992) . This effect would be indirectly responsible for an increase of c-fos in striatopallidal neurons. Nevertheless, cholinergic interneurons expressing D 5 (C. Le Moine, unpublished results) in addition to D 2 receptors (Le Moine et al., 1990b) and corticostriatal glutamatergic neurons (Gaspar et al., 1995) 
Effect of combined D 1 and D 2 agonists on c-fos expression in the striatum
Thus, the effects of D 1 or D 2 agonists probably can be attributed to both direct postsynaptic effects and indirect effects mediated by the mesencephalic dopamine neurons. However, when these drugs are combined, the effects of endogenous dopamine are likely to be masked. Indeed, in the striatum, combined treatment with D 1 and D 2 agonists potentiated c-fos expression in D 1 -containing neurons but inhibited it in D 2 -containing neurons. The fact that the combined treatment induces c-fos at 92% in D 1 -containing neurons is consistent with data obtained in conditions that enhance extracellular dopamine concentration (Graybiel et al., 1990; Young et al., 1991; Moratalla et al., 1993; Jaber et al., 1995; Wang et al., 1995; Chergui et al., 1996) .
Effect of an A 2A antagonist alone or in combination with D 1 or D 2 agonists in the striatum A 2A and D 2 receptors regulate pallidal GABA release in an opposite manner (Ferré et al., 1993; Mayfield et al., 1993 Mayfield et al., , 1996 and are colocalized in striatopallidal neurons, but not in interneurons nor on nigrostriatal terminals (Schiffmann et al., 1991; Fink et al., 1992; Augood and Emson, 1994; Svenningsson et al., 1997) . Therefore, studying the effects of A 2A receptors on striatal neurotransmission may be of interest not only to better under- Table 2 . Magnification, 640ϫ. stand adenosinergic modulation but also to delineate effects specifically related to an altered activity of striatopallidal neurons. We show here that the A 2A antagonist SCH-58261 shared with the D 2 agonist the ability to decrease c-fos expression in the striatum. This decrease occurred only in D 2 -containing neurons, suggesting that this effect is mainly postsynaptic. Indeed, unlike the D 2 agonist, the A 2A antagonist does not affect dopamine release (Ferré et al., 1993) . This supports the idea that endogenous adenosine acting at A 2A receptors regulates the constitutive expression of immediate early genes in the striatum (Svenningsson et al., 1995) .
Coadministration of the A 2A antagonist with the D 1 agonist potentiated the D 1 -induced increase in c-fos expression in D 1 -containing neurons, like treatment with D 1 and D 2 agonists. However, this combination, unlike the D 1 plus D 2 combination, caused no inhibition of D 1 -mediated c-fos induction in D 2 -containing neurons. This suggests that regulation of c-fos by dopamine is more potent than A 2A -mediated effects on these neurons in our conditions. Whereas the D 1 /D 2 combined treatment produced a change of the initial homogeneous striatal expression of c-fos into a "patchy" pattern, as previously described (Paul et al., 1992; Wang and McGinty, 1996) , the pattern of c-fos expression after the D 1 /A 2A combination was homogeneous in the striatum. These results suggest that D 2 receptors located postsynaptically on striatopallidal neurons, like the A 2A receptors, are involved in the quantitative enhancement of c-fos mRNA in striatal neurons, whereas D 2 receptors located presynaptically or on interneurons might be involved more specifically in differential dopaminergic regulations between the patch/matrix compartments. A strong tendency for a decrease of c-fos expression was found after D 1 agonist treatment, although not significant in our statistical conditions. This tendency might be attributable to the D 1 -mediated c-fos expression in striatopallidal neurons. Taken together, these data suggest that stimulation of D 1 and D 2 receptors has opposite effects on pallidal neurons also.
The combined treatment with D 1 and D 2 agonists potentiated the increase in c-fos expression induced by the D 2 agonist alone, as previously shown (Paul et al., 1992 (Paul et al., , 1995 Marshall et al., 1993) . This agrees with electrophysiological data showing that the D 1 plus D 2 coactivation is required for the maximal excitatory effect, demonstrating a potentiated effect mediated by D 1 receptors on D 2 receptor-activated responses (Walters et al., 1987) . There was also a strong induction of c-fos expression after combined treatment, using the A 2A antagonist together with the D 1 agonist. Interestingly, coadministration of A 2A antagonist together with the D 2 agonist had no synergistic effects on c-fos expression in the globus pallidus. This implies that, despite their coexpression and their well established interactions (Ferré et al., 1992 (Ferré et al., , 1993 , the D 2 and A 2A receptors are not solely the key for adenosine/ dopamine interactions in the basal ganglia. Instead, our findings suggest that the most important f unctional interactions may be between drugs that affect A 2A and dopamine receptors in distinct neuronal populations. This conclusion also has implications for our understanding of the D 1 /D 2 interactions.
Disinhibition of striatopallidal neurons is one of the mechanisms whereby c-fos is induced in globus pallidus. However, if c-fos expression can correlate with the activity of striatopallidal neurons, these neurons are likely to be stimulated rather than inhibited by combined treatments with D 1 plus D 2 agonists or D 1 agonist plus A 2A antagonist. Thus, the increase in pallidal c-fos expression may be attributable to the involvement of additional inputs to the globus pallidus. This may be attributable to an increased activity in the excitatory input from subthalamic nucleus. It has been found that NMDA receptor antagonists inhibit the induction of pallidal Fos immunoreactivity after combined administration of D 1 and D 2 agonists (Paul et al., 1992 (Paul et al., , 1995 . Thus, it might turn out that concomitant stimulation of an excitatory input and inhibition of striatopallidal neurons act in synergy to increase c-fos in globus pallidus.
Conclusion
Although c-fos generally is used as a neuronal activation marker, we demonstrate here that basal c-fos expression is upregulated by a D 1 agonist but downregulated by a D 2 agonist or an A 2A antagonist. This suggests that c-fos mRNA levels may be used as an indicator of inhibition as well as activation of a neuronal pathway. Synergistic effects have been observed in the striatal output pathways after coadministration of D 1 plus D 2 agonists or D 1 agonist plus A 2A antagonist, providing evidence for important interactions between these parallel pathways. This work gives a basis for f urther investigations to elucidate the mechanisms whereby these synergistic effects occur, especially in the globus pallidus.
